Announcements Trials
Browse Landscape

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 19Observational 2

Sponsor

Cancer Type

Gastrointestinal 1Breast 1

Conditions

HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma 1Breast Neoplasms 1

Interventions

Blood Specimen Collection 131Surveys and Questionnaires 130Specimen Handling 57Observation 55Radiotherapy 44Interviews as Topic 34Surgical Procedures, Operative 32Drug Therapy 31Biopsy 28Data Collection 26Magnetic Resonance Spectroscopy 25Nivolumab 20Watchful Waiting 20Immune Checkpoint Inhibitors 18Immunotherapy 17Magnetic Resonance Imaging 17Therapeutics 17Standard of Care 16trastuzumab deruxtecan 14Liquid Biopsy 13Tomography, X-Ray Computed 13palbociclib 13Hematologic Tests 12Restraint, Physical 12Focus Groups 11Genetic Testing 11Bevacizumab 10Positron Emission Tomography Computed Tomography 10darolutamide 10enzalutamide 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Observational × disitamab vedotin × 1 year × Clear all
NCT07490990 2026-03-24

A Real-World, Single-Arm Study Protocol of Disitamab Vedotin in Combination With Immunotherapy and Multimodal Radiation Therapy for HER2-Positive Advanced Gastric Cancer: After Second-Line Treatment Failure

West China Hospital

Not yet recruiting
30 enrolled
Gastrointestinal

HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

NCT05851677 2025-09-17

Disitamab Vedotin (RC48-ADC) in Breast Cancer

RenJi Hospital

Recruiting
45 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡